Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval Reports
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The assumption that the design of an antidepressant clinical trial affects the outcome of that trial is based on sparse data. We sought to examine if the dosing schedule, either a fixed dose or a flexible dose type, in an antidepressant clinical trial affects the frequency with which antidepressants show statistical superiority over placebo. Randomized, placebo-controlled clinical trials of nine antidepressants approved by the Food and Drug Administration between 1985 and 2000 were reviewed. These trials comprised 9313 depressed patients who participated in 51 antidepressant clinical trials consisting of 92 treatment arms with eventual approved doses. In the flexible dose trials, 59.6% (34/57) of the antidepressant treatment arms were statistically significant compared to placebo, whereas in the fixed dose trials only 31.4% (11/35) of the antidepressant treatment arms were statistically significant compared to placebo (chi(2)=6.9, df=1, p<0.01). These data suggest that the antidepressant dose schedule may influence trial outcome due in part to a significantly lower magnitude of symptom reduction with placebo in flexible dose trials (F=4.08, df=1, 48, p&<0.05) compared to fixed dose trials. Symptom reduction was similar with antidepressants in the flexible and fixed dose trials. Further, the primary function of finding a dose-response relationship was not found among the fixed dose studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bollini, P., Pampaliona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.297 · Cited by 274
Cited by
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
The circadian basis of winter depression
Lewy, A. J., Lefler, B. J., Emens, J. S., & Bauer, V. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602425103 · Cited by 451
Dworkin, R. H., Turk, D. C., Peirce-Sandner, S., Baron, R., Bellamy, N., Burke, L. B., Chappell, A., Chartier, K., Cleeland, C. S., Costello, A., et al. (2010) · Pain · doi:10.1016/j.pain.2010.02.018 · Cited by 381
Papakostas, G. I., & Fava, M. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.009 · Cited by 382
Glutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
Lisanby, S. H., Husain, M. M., Rosenquist, P. B., Maixner, D., Gutierrez, R., Krystal, A., Gilmer, W., Marangell, L. B., Aaronson, S., Daskalakis, Z. J., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.118 · Cited by 333
“…to reported effect sizes for antidepressant medications in populations where treatment resistance is not typically used as an inclusion criterion (Khan et al, 2003; Moncrieff et al, 1998, 2004), and to the anticipated efficacy of a second adequate trial of antidepressant medications after a…”
BackgroundSerotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan
Turner, E. H., Loftis, J. M., & Blackwell, A. D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.004 · Cited by 326
Avery, D. H., Holtzheimer, P. E., Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., Haynor, D. R., Claypoole, K. H., Wajdik, C., & Roy-Byrne, P. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.003 · Cited by 318
Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain
Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013) · The Journal of Pain · doi:10.1016/j.jpain.2012.10.009 · Cited by 314
“Experience fromthepsychiatric literature suggests that trials with flexible-dose designs arealmost twiceas likely todemonstrate significantdifferences between antidepressant medications and placebo than fixed-dose trials.(36) Higher placebo response rates in the fixed-dose trials might be explained by an increase in e…”
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub2 · Cited by 305
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Kennedy, S. H., & Emsley, R. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.002 · Cited by 294
Rickels, K., Pollack, M. H., Feltner, D. E., Lydiard, R. B., Zimbroff, D. L., Bielski, R. J., Tobias, K., Brock, J. D., Zornberg, G. L., & Pande, A. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.1022 · Cited by 280
Pierre Olié, J., & Kasper, S. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007766 · Cited by 256
Furukawa, T. A., Cipriani, A., Atkinson, L. Z., Leucht, S., Ogawa, Y., Takeshima, N., Hayasaka, Y., Chaimani, A., & Salanti, G. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30307-8 · Cited by 219
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190
GABAergic Control of Depression-Related Brain States
Luscher, B., & Fuchs, T. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.11.003 · Cited by 149
Depressive disorders: treatment failures and poor prognosis over the last 50 years
Blackburn, T. P. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.472 · Cited by 136
Jones, B. D. M., Razza, L. B., Weissman, C. R., Karbi, J., Vine, T., Mulsant, L. S., Brunoni, A. R., Husain, M. I., Mulsant, B. H., Blumberger, D. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25531 · Cited by 121
Lüscher, B., & Möhler, H. (2019) · F1000Research · doi:10.12688/f1000research.18758.1 · Cited by 105
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100
Hieronymus, F., Nilsson, S., & Eriksson, E. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.104 · Cited by 100
Leal, G. C., Souza-Marques, B., Mello, R. P., Bandeira, I. D., Caliman-Fontes, A. T., Carneiro, B. A., Faria-Guimarães, D., Guerreiro-Costa, L. N. F., Jesus-Nunes, A. P., Silva, S. S., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.151 · Cited by 62
Gommoll, C. P., Greenberg, W. M., & Chen, C. (2014) · Journal of Drug Assessment · doi:10.3109/21556660.2014.884505 · Cited by 43
“Khan et al.37,38 reported success rates of 59.6% for MDD trials with a flexible-dose design vs 31.4% for fixed-dose trials; conversely, an analysis by Khin et al.35 found a slightly higher success rate in fixed-dose (57”
BackgroundInfluentialDeclining efficacy in controlled trials of antidepressants: effects of placebo dropout
Schalkwijk, S., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000224 · Cited by 34
The conundrum of depression clinical trials: one size does not fit all
Khan, A., Mar, K. F., & Brown, W. A. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000229 · Cited by 30
Self-citationFurukawa, T. A., Salanti, G., Cowen, P. J., Leucht, S., & Cipriani, A. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13145 · Cited by 26
“An earlier report found that flexible-dose studies were more often able to detect statistically significant drug–placebo differences than fixed-dose studies (16).”
BackgroundSafer, D. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000564 · Cited by 19
Metadata
- Authors
- Khan, A., Khan, S. R., Walens, G., Kolts, R., & Giller, E. L.
- Venue
- Neuropsychopharmacology
- Published
- 2002-09-16
- Volume
- 28
- Issue
- 3
- Pages
- 552-557
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1967378279
- Cited by
- 158
- References
- 1
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.